Sodium-Glucose Cotransporter 2 Inhibitors Use in Patients With Liver Cirrhosis

IF 6 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Fu-Shun Yen, Ming-Chih Hou, James Cheng-Chung Wei, Yu-Han Huang, Ying-Hsiu Shih, Chun-Wei Pan, Sing-Ting Wang, Chii-Min Hwu, Chih-Cheng Hsu
{"title":"Sodium-Glucose Cotransporter 2 Inhibitors Use in Patients With Liver Cirrhosis","authors":"Fu-Shun Yen,&nbsp;Ming-Chih Hou,&nbsp;James Cheng-Chung Wei,&nbsp;Yu-Han Huang,&nbsp;Ying-Hsiu Shih,&nbsp;Chun-Wei Pan,&nbsp;Sing-Ting Wang,&nbsp;Chii-Min Hwu,&nbsp;Chih-Cheng Hsu","doi":"10.1002/dmrr.70070","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aims</h3>\n \n <p>Cirrhosis and diabetes mellitus can develop and influence each other. We conducted this study to compare the hepatic outcomes of sodium-glucose cotransporter 2 (SGLT2) inhibitor use versus no-use in patients with liver cirrhosis and type 2 diabetes.</p>\n </section>\n \n <section>\n \n <h3> Materials and Methods</h3>\n \n <p>We identified patients diagnosed with type 2 diabetes and liver cirrhosis from the Taiwan's National Health Insurance Research Database between 1 January 2000 and 31 December 2021. Multivariable-adjusted Cox proportional hazard models were used to compare the risks of decompensated cirrhosis, liver failure, cardiovascular events and mortality between SGLT2 inhibitor users and nonusers.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The mean follow-up period for SGLT2 inhibitor users and nonusers was 2.86 and 2.66 years, respectively. The incidence rates of mortality during follow-up were 29.97 versus 63.18 per 1000 person-years for SGLT2 inhibitor users and nonusers, respectively. The multivariable-adjusted models showed that SGLT2 inhibitor users had lower risks of all-cause mortality (aHR 0.47, 95% CI 0.42–0.52), decompensated cirrhosis (aHR 0.67 95% CI 0.58–0.77), liver failure (aHR 0.58, 95% CI 0.49–0.69), hepatorenal syndrome (aHR 0.54, 95% CI 0.35–0.85) and major adverse cardiovascular events (aHR 0.80, 95% CI 0.52–0.70) than nonusers. A longer cumulative duration of SGLT2 inhibitors had further lower risks of mortality and decompensated cirrhosis.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>This nationwide cohort study showed that SGLT2 inhibitor use was associated with a significantly lower risk of mortality, decompensated cirrhosis, liver failure and cardiovascular events in patients with compensated liver cirrhosis and type 2 diabetes. SGLT2 inhibitors may be an option for diabetes management in patients with compensated liver cirrhosis.</p>\n </section>\n </div>","PeriodicalId":11335,"journal":{"name":"Diabetes/Metabolism Research and Reviews","volume":"41 5","pages":""},"PeriodicalIF":6.0000,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes/Metabolism Research and Reviews","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/dmrr.70070","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Aims

Cirrhosis and diabetes mellitus can develop and influence each other. We conducted this study to compare the hepatic outcomes of sodium-glucose cotransporter 2 (SGLT2) inhibitor use versus no-use in patients with liver cirrhosis and type 2 diabetes.

Materials and Methods

We identified patients diagnosed with type 2 diabetes and liver cirrhosis from the Taiwan's National Health Insurance Research Database between 1 January 2000 and 31 December 2021. Multivariable-adjusted Cox proportional hazard models were used to compare the risks of decompensated cirrhosis, liver failure, cardiovascular events and mortality between SGLT2 inhibitor users and nonusers.

Results

The mean follow-up period for SGLT2 inhibitor users and nonusers was 2.86 and 2.66 years, respectively. The incidence rates of mortality during follow-up were 29.97 versus 63.18 per 1000 person-years for SGLT2 inhibitor users and nonusers, respectively. The multivariable-adjusted models showed that SGLT2 inhibitor users had lower risks of all-cause mortality (aHR 0.47, 95% CI 0.42–0.52), decompensated cirrhosis (aHR 0.67 95% CI 0.58–0.77), liver failure (aHR 0.58, 95% CI 0.49–0.69), hepatorenal syndrome (aHR 0.54, 95% CI 0.35–0.85) and major adverse cardiovascular events (aHR 0.80, 95% CI 0.52–0.70) than nonusers. A longer cumulative duration of SGLT2 inhibitors had further lower risks of mortality and decompensated cirrhosis.

Conclusions

This nationwide cohort study showed that SGLT2 inhibitor use was associated with a significantly lower risk of mortality, decompensated cirrhosis, liver failure and cardiovascular events in patients with compensated liver cirrhosis and type 2 diabetes. SGLT2 inhibitors may be an option for diabetes management in patients with compensated liver cirrhosis.

钠-葡萄糖共转运蛋白2抑制剂在肝硬化患者中的应用
目的肝硬化与糖尿病是相互发展、相互影响的。我们进行了这项研究,以比较在肝硬化和2型糖尿病患者中使用钠-葡萄糖共转运蛋白2 (SGLT2)抑制剂与不使用SGLT2抑制剂的肝脏结局。​采用多变量校正Cox比例风险模型比较SGLT2抑制剂使用者和非使用者失代偿性肝硬化、肝功能衰竭、心血管事件和死亡率的风险。结果SGLT2抑制剂使用者和非使用者的平均随访时间分别为2.86年和2.66年。在随访期间,SGLT2抑制剂使用者和非使用者的死亡率分别为每1000人年29.97和63.18。多变量调整模型显示,SGLT2抑制剂使用者的全因死亡率(aHR 0.47, 95% CI 0.42-0.52)、失代偿性肝硬化(aHR 0.67, 95% CI 0.58 - 0.77)、肝功能衰竭(aHR 0.58, 95% CI 0.49-0.69)、肝肾综合征(aHR 0.54, 95% CI 0.35-0.85)和主要不良心血管事件(aHR 0.80, 95% CI 0.52-0.70)的风险低于非使用者。SGLT2抑制剂的累积持续时间越长,死亡率和失代偿性肝硬化的风险就越低。结论:这项全国性队列研究显示,在代偿性肝硬化和2型糖尿病患者中,使用SGLT2抑制剂与死亡率、失代偿性肝硬化、肝功能衰竭和心血管事件的风险显著降低相关。SGLT2抑制剂可能是代偿性肝硬化患者糖尿病治疗的一种选择。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Diabetes/Metabolism Research and Reviews
Diabetes/Metabolism Research and Reviews 医学-内分泌学与代谢
CiteScore
17.20
自引率
2.50%
发文量
84
审稿时长
4-8 weeks
期刊介绍: Diabetes/Metabolism Research and Reviews is a premier endocrinology and metabolism journal esteemed by clinicians and researchers alike. Encompassing a wide spectrum of topics including diabetes, endocrinology, metabolism, and obesity, the journal eagerly accepts submissions ranging from clinical studies to basic and translational research, as well as reviews exploring historical progress, controversial issues, and prominent opinions in the field. Join us in advancing knowledge and understanding in the realm of diabetes and metabolism.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信